Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.8593 | 0.5 |
Brugia malayi | hypothetical protein | 0.002 | 0.1458 | 0.1458 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9606 | 0.9606 |
Echinococcus multilocularis | musashi | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 2.2387 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 23.9341 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.